Lung cancer is the leading cause of cancer-related deaths worldwide. Based on status quo detection strategies and therapies, only 16% of patients diagnosed last year with lung cancer will survive for five years. Lung cancer is the result of a wide range of genetic changes, many of which indirectly affect protein kinase signaling pathways that disrupt the normal homeostasis of cell proliferation and apoptosis. Protein kinases are now an important class of targets for lung cancer therapy. The purpose of the experiments proposed here is to develop and validate quantitative methods in phosphoproteomics capable of probing differences in cellular signaling in lung tumors that correlate with patient outcomes. To do this, we will i) develop a quantitative phosphoproteomics technology for clinical lung cancer specimens, ii) develop phospho-multiple reaction monitoring (p-MRM) methods that target substrates of clinically relevant kinases, and iii) deploy these methods to study differences in cellular signaling in tumors from a limited cohort of non-small cell lung cancer patients. We anticipate that the successful conduct of the experiments proposed here will provide translational scientists and thoracic oncologists with an entirely new dimension of biomedical information which will enable the discovery of new treatment strategies, improve assessments of patient responsiveness to kinase inhibitor therapies at the molecular level, and allow for highly individualized decisions regarding patient care.
Lung cancer is the leading cause of cancer-related deaths worldwide. By developing new approaches to look at how cellular signals correlate with the outcome of disease, the research presented here is designed to accelerate the clinical discovery and validation of new therapeutic strategies for the treatment of lung cancer.
|Kettenbach, Arminja N; Schlosser, Kate A; Lyons, Scott P et al. (2018) Global assessment of its network dynamics reveals that the kinase Plk1 inhibits the phosphatase PP6 to promote Aurora A activity. Sci Signal 11:|
|Grassetti, Andrew V; Hards, Rufus; Gerber, Scott A (2017) Offline pentafluorophenyl (PFP)-RP prefractionation as an alternative to high-pH RP for comprehensive LC-MS/MS proteomics and phosphoproteomics. Anal Bioanal Chem 409:4615-4625|
|Cullati, Sierra N; Kabeche, Lilian; Kettenbach, Arminja N et al. (2017) A bifurcated signaling cascade of NIMA-related kinases controls distinct kinesins in anaphase. J Cell Biol 216:2339-2354|
|Bahl, Christopher D; Hvorecny, Kelli L; Morisseau, Christophe et al. (2016) Visualizing the Mechanism of Epoxide Hydrolysis by the Bacterial Virulence Enzyme Cif. Biochemistry 55:788-97|
|Adamo, Mark E; Gerber, Scott A (2016) Tempest: Accelerated MS/MS Database Search Software for Heterogeneous Computing Platforms. Curr Protoc Bioinformatics 55:13.29.1-13.29.23|
|Koeppen, Katja; Hampton, Thomas H; Jarek, Michael et al. (2016) A Novel Mechanism of Host-Pathogen Interaction through sRNA in Bacterial Outer Membrane Vesicles. PLoS Pathog 12:e1005672|
|Sullivan, Jaclyn M; Havrda, Matthew C; Kettenbach, Arminja N et al. (2016) Phosphorylation Regulates Id2 Degradation and Mediates the Proliferation of Neural Precursor Cells. Stem Cells 34:1321-31|
|Johnson, Michael E; Grassetti, Andrew V; Taroni, Jaclyn N et al. (2016) Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. Arthritis Res Ther 18:27|
|Kettenbach, Arminja N; Deng, Lin; Wu, Youjun et al. (2015) Quantitative phosphoproteomics reveals pathways for coordination of cell growth and division by the conserved fission yeast kinase pom1. Mol Cell Proteomics 14:1275-87|
|Kettenbach, Arminja N; Sano, Hiroyuki; Keller, Susanna R et al. (2015) SPECHT - single-stage phosphopeptide enrichment and stable-isotope chemical tagging: quantitative phosphoproteomics of insulin action in muscle. J Proteomics 114:48-60|
Showing the most recent 10 out of 16 publications